Colorectal Cancer - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Colorectal Cancer Emerging Therapy and TPP Insights

Thelansis's "Colorectal Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Colorectal Cancer Overview

Colorectal cancer (CRC) is a malignancy of the colon or rectum shaped by diverse genetic and epigenetic changes. It may cause altered bowel habits, rectal bleeding, abdominal discomfort, anemia, or weight loss, although early disease can be asymptomatic. Treatment depends on tumor site, stage, molecular profile, and patient fitness; localized disease is commonly managed with surgery, with chemotherapy or radiotherapy used as indicated. Advanced disease may require systemic chemotherapy, biologic agents, or immunotherapy. Testing for mismatch-repair/microsatellite-instability status, RAS and BRAF mutations, HER2, and rare gene fusions can guide treatment. Options include checkpoint inhibitors for MSI-H/dMMR tumors, BRAF-directed combinations, and KRAS G12C-targeted therapy for eligible patients. In 2026, U.S. approval expanded to atezolizumab plus chemotherapy after resection of stage III dMMR colon cancer. Resistance and recurrence remain important challenges.

Market Overview

• The Spain colorectal cancer market is projected to grow from $572M in 2026 to $705M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies and immunotherapy in eligible patients
• Advances in precision medicine and biomarker-guided treatment
• Future growth will depend on treatments that improve survival and expand options for patients with advanced disease.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Bristol-Myers Squibb
• Syndax Pharmaceuticals
• Cardiff Oncology
• Lyell Immunopharma, Inc.
• Leap Therapeutics, Inc.
• Exelixis
• Takeda
• AbbVie
• NGM Biopharmaceuticals, Inc.
• Genentech, Inc.
• BeiGene
• Merck Sharp & Dohme LLC
• Redx Pharma Ltd.
• Akeso
• Vividion Therapeutics, Inc.
• NovaOnco Therapeutics Co., Ltd.
• Amgen
• Novartis Pharmaceuticals